Coronavirus & stuff

Return_of_the_STAR wrote:What are we expecting tomorrow? Just a delay in opening or some slightly stricter measures again?

Stuart wrote:

Return_of_the_STAR wrote:What are we expecting tomorrow? Just a delay in opening or some slightly stricter measures again?

1 month delay, allow time for more vaccinations

That's not a growth wrote:It's the least they can do, they also need to reaffirm how they're going to reverse this uptick without just waiting for second doses to be more prevalent as that'll be late summer. If stopping easing were enough then it wouldn't still be growing, as they haven't eased extra in weeks.

Green Gecko wrote:I think the data said Oxford AZ is less effective at reducing symptoms and transmission for the Indian variant but does very much protect against what would be hospital admission?

Novavax has said its COVID-19 vaccine is 100% effective in protecting against "moderate and severe disease" following its phase three trial results.

The American biotechnology company said the trial had shown its vaccine was also 93% effective against circulating variants of concern and variants of interest, and 91% effective in protecting high-risk populations.

The trial, which involved 29,960 participants across 119 sites across the US and Mexico, showed 90.4% efficacy overall.

The study placed an emphasis on having participants that represented communities and demographics most impacted by the disease.

Within the group, 77 people tested positive for COVID-19, 63 were on a placebo and 14 had received the vaccine.

All of the cases in the vaccinated group were defined as "mild" while 10 "moderate" cases and four "severe" cases were observed among those who had been given the placebo.

Preliminary safety data from the study also showed "generally mild and moderate" pain and tenderness around the injection site, as well as fatigue, muscle pain and headache were the most common symptoms in participants.

Gregory Glenn, president of research and development at Novavax, said: "Our vaccine will be a critical part of the solution to COVID-19 and we are grateful to the study participants and trial staff who made this study possible, as well as our supporters, including the US government."

The company remains on track to be able to manufacture 100 million vaccine doses a month by the end of September and 150 million doses by the end of the year, once it receives regulatory approvals.

President and chief executive officer of Novavax, Stanley Erck, said the results show it is "one step closer to addressing the critical and persistent global public health need" for additional COVID-19 jabs.

He added: "Novavax continues to work with a sense of urgency to complete our regulatory submissions and deliver this vaccine, built on a well understood and proven platform, to a world that is still in great need of vaccines."

Grumpy David wrote:https://news.sky.com/story/covid-19-novavax-jab-100-effective-in-protecting-against-moderate-and-severe-disease-trial-results-suggest-12332248

Novavax jab 100% effective in protecting against moderate and severe disease, trial results suggest

President of research and development at Novavax, said: "Our vaccine will be a critical part of the solution to COVID-19".

Novavax has said its COVID-19 vaccine is 100% effective in protecting against "moderate and severe disease" following its phase three trial results.

The American biotechnology company said the trial had shown its vaccine was also 93% effective against circulating variants of concern and variants of interest, and 91% effective in protecting high-risk populations.

The trial, which involved 29,960 participants across 119 sites across the US and Mexico, showed 90.4% efficacy overall.

The study placed an emphasis on having participants that represented communities and demographics most impacted by the disease.

Within the group, 77 people tested positive for COVID-19, 63 were on a placebo and 14 had received the vaccine.

All of the cases in the vaccinated group were defined as "mild" while 10 "moderate" cases and four "severe" cases were observed among those who had been given the placebo.

Preliminary safety data from the study also showed "generally mild and moderate" pain and tenderness around the injection site, as well as fatigue, muscle pain and headache were the most common symptoms in participants.

Gregory Glenn, president of research and development at Novavax, said: "Our vaccine will be a critical part of the solution to COVID-19 and we are grateful to the study participants and trial staff who made this study possible, as well as our supporters, including the US government."

The company remains on track to be able to manufacture 100 million vaccine doses a month by the end of September and 150 million doses by the end of the year, once it receives regulatory approvals.

President and chief executive officer of Novavax, Stanley Erck, said the results show it is "one step closer to addressing the critical and persistent global public health need" for additional COVID-19 jabs.

He added: "Novavax continues to work with a sense of urgency to complete our regulatory submissions and deliver this vaccine, built on a well understood and proven platform, to a world that is still in great need of vaccines."

Novavax are meant to apply for approval no earlier than 1st July.

I'd imagine that phase 3 variants of concern won't factor in the Indian variant as it's so new but would cover the Kent, South African and Brazilian variant.

They are also testing it as a booster variant when a different vaccine has previously been used. Early data shows the Oxford vaccine followed by the BioNtech vaccine is almost as good as the BioNtech x2 however slightly higher chance of getting a fever and/or headache after the booster dose.

rinks wrote:After my day as a zombie following the first AZ dose, the silver lining was that the second shot is said to have fewer side effects. Now I can look forward to another trip to hell with this new Zombrex.